YZi Labs Invests in Renewal Bio, Pioneering Regenerative Medicine
YZi Labs made its first biotech investment in 2025, backing Renewal Bio, a company developing next-generation solutions for organ and cell shortages. This biotech investment comes at a time when regenerative medicine is gaining momentum.
Addressing the Global Organ Shortage
Every year, over 150,000 organ transplants happen worldwide. Sadly, this meets only about 10% of the demand. Even in the United States, organ shortages are severe. Millions of people are always waiting for compatible donors. Sometimes, they even have to face immune rejection after a transplant.
YZi Labs (formerly Binance Labs) has invested in regenerative medicine firm Renewal Bio, marking its first biotech investment in 2025. Renewal Bio uses its Stembroid™ platform to create DNA-identical human cells and tissues from patients’ own cells to tackle the global organ…
Renewal Bio aims to close this gap. Using its Stembroid™ platform, it creates DNA-identical human cells from a patient’s own cells. This means a scalable, immune-compatible alternative to donor organs is now within reach.
How Stembroid™ Technology Works
Renewal Bio’s technology reprograms ordinary skin or blood cells into stem cells. Then, it develops them in a three-dimensional system that resembles early human development. This process enables growth to be guided by nature, resulting in functional cells suitable for transplantation. With this method, it is possible to generate important cell types, including blood, liver, heart, and pancreatic cells.
YZi Labs Makes First Biotech Investment in Renewal Bio to Address Global Organ Shortages!@YZiLabs has announced its first-ever biotech investment, backing Renewal Bioz a regenerative medicine company pioneering lab-grown, DNA-identical human cells and tissues to combat global… pic.twitter.com/WMFvWpGkvM
Although the company’s long-term vision spans decades, Renewal Bio has immediate objectives. The focus now is on hematopoietic stem cells (HSCs), which are vital for bone marrow transplants and the treatment of leukemia. Such cells may benefit more than 20,000 patients annually who need matching donations.
A meaningful milestone for @yzilabs 💛 The team’s first biotech investment since expanding our mandate in 2025. Each year, millions wait for compatible organs that may never come. Renewal Bio is reimagining healing — where the body itself becomes the cure. Full story ↓ https://t.co/KiO57jy4ld
This new investment by YZi Labs will speed up pre-clinical trials of HSCs. It will also fund research on liver, heart, and pancreatic cells. Additionally, it will expand labs and prepare for GMP-grade production, bringing treatments closer to patients.
Significance of the Biotech Investment
According to Jane He, General Partner at YZi Labs, the work of Renewal Bio involves using a person’s own cells to self-heal and self-renew. Having them provides an investment in the future of how we care, heal, and live longer and healthier lives.
Vladislav Krupalnik also stated that their aim is to make regenerative medicine more than a dream. They intend to make it a reality, scale it, and make it available to everyone who needs it.
https://t.co/M83AmQat5c
Conclusion
The 2025 Biotech investment in Renewal Bio is a strong indicator that YZi Labs is entering the regenerative medicine space. Through its support, YZi Labs is contributing to the progress of science by taking scientific advancements closer to patients. This is not only a financial investment but also an investment in human health and longevity.